Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

66 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Announcement from Crown Energy's Annual General Meeting
AQ
Notice to the Annual General Meeting 2023 in Crown Energy AB (publ)
AQ
Novocure Announces Organizational Changes to Prepare for Future Growth
BU
Novocure Announces Executive Changes
CI
Novocure to Participate in Upcoming Investor Conferences
BU
Announcement from Crown Energy's annual general meeting
AQ
Transcript : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
BU
Novocure : Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer - Form 8-K
PU
Transcript : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
BU
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
BU
Novocure : Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
BU
Crown Energy : Announcement from Crown Energy’s annual general meeting
PU
Crown Energy : Announcement from Crown Energy's annual general meeting
AQ
Crown Energy : Notice to the Annual General Meeting 2021 in Crown Energy AB (publ)
AQ
Transcript : NovoCure Limited, Q4 2020 Earnings Call, Feb 25, 2021
NovoCure : First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
BU
Novocure : Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting
BU
Transcript : NovoCure Limited - Shareholder/Analyst Call
Novocure : Announces Agenda for Virtual Research and Development Day
BU
Transcript : NovoCure Limited, Q3 2020 Earnings Call, Oct 29, 2020
Transcript : NovoCure Limited, Q2 2020 Earnings Call, Jul 30, 2020
Crown Energy : Announcement from Crown Energy’s annual general meeting
PU
Crown Energy : Announcement from Crown Energy's annual general meeting
AQ
Crown Energy : Notice to the Annual General Meeting 2020 in Crown Energy AB (publ)
AQ
Transcript : NovoCure Limited, Q1 2020 Earnings Call, Apr 30, 2020
Crown Energy : Notice to the Annual General Meeting 2020 in Crown Energy AB (publ)
AQ
Transcript : NovoCure Limited, Q4 2019 Earnings Call, Feb 27, 2020
Transcript : NovoCure Limited, Q3 2019 Earnings Call, Oct 31, 2019
Novocure : Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
BU
Transcript : NovoCure Limited, Q2 2019 Earnings Call, Jul 25, 2019
Transcript : NovoCure Limited, Q1 2019 Earnings Call, May 02, 2019
Novocure :’s Chief Science Officer Retires after 17 Years of Service
BU
Novocure Announces Executive Changes
CI
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients
GL
Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium
GL
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
GL
Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane® in Patients Newly Diagnosed With Metastatic Pancreatic Cancer
GL
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
GL
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
GL
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
GL
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
GL
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress
GL
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
GL
Crown Energy : Interim Report Jan-March 2017
PU
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
GL
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
GL
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress
GL
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer
GL
No results for this search
  1. Stock Market
  2. Advanced search
  3. Ely Benaim
  4. News